Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Sees Large Drop in Short Interest
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Sees Large Drop in Short Interest
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) saw a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 10,340,000 shares, a drop of 21.7% from the July 31st total of 13,200,000 shares. Based on an average daily trading volume, of 26,080,000 shares, the short-interest ratio is presently 0.4 days.
阿莱纳制药公司(纳斯达克：ALNA-GET评级)看到空头股数在8月份大幅下降。截至8月15日，空头股数共有10，34万股，较7月31日的13,200,000股减少21.7%。以日均成交量2608万股计算，目前短息比为0.4天。
Allena Pharmaceuticals Price Performance
Allena制药公司的价格表现
NASDAQ:ALNA remained flat at $0.10 during trading hours on Friday. The company's stock had a trading volume of 3,366,902 shares, compared to its average volume of 14,194,126. The company's 50 day moving average is $0.14 and its 200 day moving average is $0.21. Allena Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $1.17.
纳斯达克：周五交易时段，Alna持平于0.1美元。该公司股票的成交量为3366,902股，而其平均成交量为14,194,126股。该公司的50日移动均线切入位在0.14美元，200日移动均线切入位在0.21美元。Allena PharmPharmticals的52周低点为0.07美元，52周高位为1.17美元。
Institutional Inflows and Outflows
机构资金流入和流出
An institutional investor recently bought a new position in Allena Pharmaceuticals stock. Millennium Management LLC bought a new position in shares of Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 173,798 shares of the company's stock, valued at approximately $33,000. Millennium Management LLC owned about 0.16% of Allena Pharmaceuticals as of its most recent SEC filing. 22.52% of the stock is owned by institutional investors and hedge funds.
一家机构投资者最近买入了Allena PharmPharmticals股票的新头寸。根据千禧管理有限责任公司在第二季度购买了阿莱纳制药公司(纳斯达克：ALNA-GET评级)的股票在第二季度，该公司在其最近披露的美国证券交易委员会。该公司购买了173,798股该公司股票，价值约33,000美元。截至最近提交的美国证券交易委员会申报文件，Millennium Management LLC持有Allena PharmPharmticals约0.16%的股份。22.52%的股票由机构投资者和对冲基金持有。
Allena Pharmaceuticals Company Profile
Allena制药公司简介
Allena Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
Allena制药公司是一家生物制药公司，在美国发现、开发和商业化口服酶疗法，用于治疗罕见和严重的代谢和肾脏疾病患者。它的主要候选产品是ALLN-346，这是一种新型的尿酸降解酶，适用于晚期慢性肾脏疾病中的高尿酸血症和痛风患者。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Allena Pharmaceuticals (ALNA)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
- 免费获取StockNews.com关于Allena制药的研究报告(Alna)
- 为什么进军高级汽车零部件可能是一个机会
- MarketBeat：回顾中的一周8/22-8/26
- 机构买入让Marvell科技陷入低谷
- 戴尔股票因销售疲软而回落，跌入可怕的价值
- Dollar General的拉力赛有三个理由
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Allena PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Allena制药和相关公司的最新新闻和分析师评级的每日简要摘要。